Predict your next investment

Venture Capital
pacifichorizon.com

See what CB Insights has to offer

Investments

37

Portfolio Exits

4

Funds

10

About Pacific Horizon Ventures

Founded in 1993, Pacific Horizon Ventures is a venture capital financing firm. Pacific Horizon Ventures invests in early stage, seed, start-up companies with a preference for companies located in Canada, midwest US, northeast US, southeast US, west. They primarily engage in the following transaction types: acquisition / expansion financing.

Pacific Horizon Ventures Headquarter Location

701 Fifth Avenue Suite 4970

Seattle, Washington, 98104,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Pacific Horizon Ventures News

Venture-backed Koronis Plans I.P.O.

Mar 14, 2011

March 14, 2011 Koronis Pharmaceuticals, a venture-backed developer of drugs for HIV, is planning an initial public offering in London for later this year, or early 2012, Reuters reported. Seattle-based Koronis has raised $43 million to date from investors. It is majority-owned by Pacific Horizon Ventures, a Seattle-based venture capital firm, Reuters said. The company’s drugs are designed to accelerate mutation of the virus that causes AIDS to the point where it collapses, Reuters wrote. (Reuters) – Koronis Pharmaceuticals, a privately held U.S. biotech firm working on a new kind of HIV drug, is looking to list in London later this year or early in 2012, its chief executive said. Seattle-based Koronis — pioneering a new HIV drug designed to accelerate mutation of the virus that causes AIDS to the point where it collapses — needs around $15 million to take its experimental product to the next stage of clinical tests. CEO Donald Elmer said he had been in talks with banks in London because raising small sums of that size was no longer feasible on the Nasdaq market in the United States, given the heavy costs of maintaining a listing there. He aims to raise the cash needed to take Koronis’s “viral decay acceleration” drug KP-1461 into further mid-stage Phase II studies via either an initial public offering (IPO) on London’s Alternative Investment Market (AIM) or by reversing into a listed entity with a cash balance. “The practical problem today is that Nasdaq is out of reach for many companies that are at the size of Koronis and the AIM market is an ideal intermediate rung for company looking to raise 10-15 million pounds,” he said in a telephone interview. So far, KP-1461 has been tested in short clinical trials on around 80 patients with no ill-effect. Now Koronis needs to conduct longer-term tests to see if it really can reduce the amount of virus circulating in patients’ blood. If it works, the new drug could mark a major change in HIV/AIDS treatment. Existing drugs all work by suppressing virus function and must be taken in life-long cocktail combinations. KP-1461 would be the first non-suppressive therapy. Katherine Xu, an analyst at Wedbush Securities, said in a research note in January that the approach was potentially “game changing” for the $12 billion-a-year HIV market, although it was still at a very early stage and therefore highly uncertain. Leading players in HIV treatment at present include Gilead (GILD.O) and ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK.L) and Pfizer (PFE.N). Koronis has to date raised $43 million in a series of private fund-raisings. It is majority-owned by Pacific Horizon Ventures, a Seattle-based venture capital firm. (Editing by Louise Heavens) © 2015 Buyouts Insider / Argosy Group LLC

Pacific Horizon Ventures Investments

37 Investments

Pacific Horizon Ventures has made 37 investments. Their latest investment was in iScience Interventional as part of their Growth Equity - II on August 8, 2011.

CBI Logo

Pacific Horizon Ventures Investments Activity

investments chart

Pacific Horizon Ventures Portfolio Exits

4 Portfolio Exits

Pacific Horizon Ventures has 4 portfolio exits. Their latest portfolio exit was CoImmune on February 07, 2014.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/7/2014

IPO

$99M

3

12/5/2007

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

6/11/2004

IPO

Subscribe to see more

Subscribe to see more

0

10/17/2003

Acquired

Subscribe to see more

Subscribe to see more

0

Date

2/7/2014

12/5/2007

6/11/2004

10/17/2003

Exit

IPO

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

0

0

0

Pacific Horizon Ventures Fund History

10 Fund Histories

Pacific Horizon Ventures has 10 funds, including Koronis Antiviral Partners II LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2011

Koronis Antiviral Partners II LP

Multi-Stage Venture Capital

Closed

$1M

1

9/1/2008

Koronis Antiviral Partners LP

Multi-Stage Venture Capital

Closed

$2M

1

8/29/2007

Anti-Viral Limited Partners LP

Multi-Stage Venture Capital

Closed

$16M

1

7/18/2006

Pacific Horizon Annex Partners II LP

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2005

Pacific Horizon Ventures IV LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/31/2011

9/1/2008

8/29/2007

7/18/2006

12/31/2005

Fund

Koronis Antiviral Partners II LP

Koronis Antiviral Partners LP

Anti-Viral Limited Partners LP

Pacific Horizon Annex Partners II LP

Pacific Horizon Ventures IV LP

Fund Type

Multi-Stage Venture Capital

Multi-Stage Venture Capital

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Closed

Closed

Closed

Subscribe to see more

Subscribe to see more

Amount

$1M

$2M

$16M

$99M

$99M

Sources

1

1

1

10

10

Pacific Horizon Ventures Team

6 Team Members

Pacific Horizon Ventures has 6 team members, including current Chief Financial Officer, Gene Rowland.

Name

Work History

Title

Status

Gene Rowland

Chief Financial Officer

Current

Donald J. Elmer

Managing Partner

Current

Richard Carone

General Partner

Former

J. Douglas Eplett

EW Healthcare Partners

General Partner

Former

Bruce Jackson

General Partner

Former

Name

Gene Rowland

Donald J. Elmer

Richard Carone

J. Douglas Eplett

Bruce Jackson

Work History

EW Healthcare Partners

Title

Chief Financial Officer

Managing Partner

General Partner

General Partner

General Partner

Status

Current

Current

Former

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.